Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA7 | P43166 | 1/20 | 0.47 |
| ▸ | CTSL | P07711 | 2/20 | 0.40 |
| ▸ | CTSB | P07858 | 1/20 | 0.40 |
| ▸ | CTSS | P25774 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.38 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.38 |
| ▸ | PSEN1 | P49768 | 2/20 | 0.38 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.38 |
| ▸ | APH1B | Q8WW43 | 2/20 | 0.38 |
| ▸ | NCSTN | Q92542 | 2/20 | 0.38 |
| ▸ | APH1A | Q96BI3 | 2/20 | 0.38 |
| ▸ | PSENEN | Q9NZ42 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26996474 | 0.81 | CA1 (0.34) | CA1CA2CA7CTSLCTSB | |
| SCHEMBL19522058 | 0.81 | CA1 (0.33) | CA1CA2CA7TP53 | |
| SCHEMBL787984 | 0.78 | CA1 (0.57) | CA1CA2CA7CTSLCTSB | |
| SCHEMBL10724721 | 0.76 | CA1 (0.55) | CA1CA2CA7CTSLCTSB | |
| SCHEMBL5564464 | 0.76 | CA1 (0.55) | CA1CA2CA7CTSLCTSB | |
| SCHEMBL19618687 | 0.76 | CA1 (0.55) | CA1CA2CA7CTSLCTSB | |
| SCHEMBL741043 | 0.76 | CA1 (0.55) | CA1CA2CA7CTSLCTSB | |
| SCHEMBL10724727 | 0.76 | CA1 (0.55) | CA1CA2CA7CTSLCTSB | |
| SCHEMBL19522055 | 0.76 | CA1 (0.33) | CA1CA2CA7 | |
| SCHEMBL4178638 | 0.76 | CA1 (0.44) | CA1CA2CA7CTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11786504-B2 | Taxane analogs for the treatment of brain cancer | TAPESTRY PHARMACEUTICALS, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-20210401797-A1 | Taxane Analogs for the Treatment of Brain Cancer | TAPESTRY PHARMACEUTICALS, INC. (US) | 2021-12-30 | — | — | US | disclosed |
| US-10450323-B2 | Biologically active taxane analogs and methods of treatment by oral administration | TAPESTRY PHARMACEUTICALS, INC. (US) | 2019-10-22 | — | — | US | disclosed |
| US-20180105535-A1 | Biologically Active Taxane Analogs and Methods of Treatment by Oral Administration | TAPESTRY PHARMACEUTICALS, INC. | 2018-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210401797-A1 | Taxane Analogs for the Treatment of Brain Cancer | TUBB, TUBB2A, TUBB1 | CA1 2698/4885CA2 3583/4885CA7 2691/4885 |
| US-20180105535-A1 | Biologically Active Taxane Analogs and Methods of Treatment by Oral Administration | DPYD, DUT, TOP2B | CA1 2682/4885CA2 4099/4885CA7 1437/4885 |
| US-10450323-B2 | Biologically active taxane analogs and methods of treatment by oral administration | DPYD, DUT, TOP2B | CA1 2682/4885CA2 4099/4885CA7 1437/4885 |
| US-11786504-B2 | Taxane analogs for the treatment of brain cancer | TUBB, TUBB2A, TUBB1 | CA1 2698/4885CA2 3583/4885CA7 2691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.